Hantavirus Treatment & Vaccine Development

Supportive Care and Clinical Management

HFRS Management

Supportive care for HFRS requires meticulous management across the five clinical phases of the disease. During the febrile and hypotensive phases, careful fluid management is critical to maintain adequate tissue perfusion without precipitating pulmonary edema. Renal replacement therapy, including intermittent hemodialysis or continuous venovenous hemofiltration, is often required during the oliguric phase when acute kidney injury reaches its peak. Early recognition and aggressive supportive care have significantly reduced HFRS mortality from over 15% to below 5% in well-resourced settings. Platelet transfusion may be required for severe thrombocytopenia, and vasopressors such as norepinephrine are used for refractory hypotension that does not respond to fluid resuscitation alone.

Monitoring of serum creatinine, blood urea nitrogen, electrolytes, platelet count, and urinary output guides the timing of dialysis initiation. In severe HFRS cases, multiorgan dysfunction involving the liver, pancreas, and central nervous system may develop, requiring a comprehensive multidisciplinary intensive care approach. The polyuric phase, during which renal function recovers, requires vigilant fluid and electrolyte replacement to prevent hypovolemia and electrolyte imbalances from massive diuresis.

HPS Management

HPS management requires intensive care unit admission with mechanical ventilation, extracorporeal membrane oxygenation (ECMO) for severe cardiopulmonary failure, and aggressive hemodynamic monitoring using pulmonary artery catheters or pulse contour analysis. The rapid progression from nonspecific prodromal symptoms to fulminant noncardiogenic pulmonary edema and cardiogenic shock can occur within hours, necessitating early clinical suspicion and immediate escalation of care. ECMO has been shown to improve survival in severe HPS cases, with reported survival rates exceeding 60% when initiated before the onset of irreversible shock.

Unlike HFRS, where renal support is the primary intervention, HPS treatment centers on cardiopulmonary support. Inotropic agents such as dobutamine may be used to support cardiac output, while careful fluid management aims to minimize pulmonary edema without compromising end-organ perfusion. The use of inhaled nitric oxide has been reported in case series as an adjunct therapy for severe hypoxemia in HPS, though controlled clinical trial data are lacking.

Vaccine Development

Vaccine development against hantaviruses has followed multiple platform strategies, each with distinct advantages and limitations. In Asia, inactivated whole-virus vaccines based on Hantaan virus and Seoul virus have been licensed and used in China and South Korea for over a decade, demonstrating safety and immunogenicity in millions of vaccinees. However, these vaccines require multiple doses and booster shots to maintain protective immunity, and their efficacy against all pathogenic hantavirus species remains limited due to antigenic differences between Old World and New World hantaviruses.

Table 1. Hantavirus Vaccine Candidates in Development

Emerging Vaccine Platforms

The success of mRNA vaccine technology during the COVID-19 pandemic has revitalized interest in mRNA-based hantavirus vaccines. Preclinical studies have demonstrated that mRNA vaccines encoding hantavirus glycoproteins can elicit potent neutralizing antibody responses and protect animal models from lethal challenge. The modular nature of mRNA technology enables rapid development of multivalent formulations targeting multiple hantavirus species simultaneously, addressing the key challenge of broad cross-protection. Virus-like particle (VLP) vaccines represent another promising approach, presenting hantavirus antigens in their native trimeric conformation on the particle surface to mimic the authentic virion structure and elicit conformationally correct neutralizing antibodies.

Challenges in Vaccine Development

The geographic heterogeneity of hantavirus disease burden presents an additional challenge for vaccine development and commercialization. HFRS is primarily endemic in Asia and parts of Europe, while HPS is concentrated in the Americas, meaning that market incentives differ across regions and a single vaccine formulation may need to address different target populations and regulatory requirements. Collaborative international initiatives, including WHO prequalification pathways and public-private partnerships, will be essential to ensure that effective hantavirus vaccines reach the populations that need them most.

Hantavirus vaccine development faces several unique challenges. The antigenic diversity among hantavirus species means that a vaccine targeting one species may not provide cross-protection against others. The glycoproteins Gn and Gc contain the principal neutralizing epitopes but are highly variable across species, while the nucleocapsid protein is more conserved but elicits primarily non-neutralizing T cell responses that contribute to cellular immunity rather than direct virus neutralization. Achieving broad cross-protection remains a key goal, and researchers are exploring conserved epitope-based approaches, mosaic antigen designs, and multivalent formulations.

Another significant challenge is the lack of established hantavirus animal models that fully recapitulate human disease. While Peromyscus maniculatus serves as a natural host for Sin Nombre virus studies, and Syrian hamsters develop ANDV-induced HPS-like disease that closely mirrors human cardiopulmonary pathology, no single model adequately represents all aspects of hantavirus pathogenesis in humans. This limitation complicates preclinical efficacy evaluation and regulatory approval pathways for new vaccine candidates.

Figure 3. Structural basis for hantavirus neutralization by vaccine-elicited antibodies. (Puumala et al., 2025)

View more Hantavirus VLPs